(Q24241252)

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

Oral budesonide as maintenance therapy in Crohn's disease--results of a 12-month study. Global Budesonide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

Oral budesonide significantly improves water absorption in patients with ileostomy for Crohn disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

Anti-inflammatory actions of steroids: molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

Inflammatory bowel disease: clinical aspects and established and evolving therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

Assessing the quality of randomized trials: reliability of the Jadad scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

A simple index of Crohn's-disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

Design issues and outcomes in IBD clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

Budesonide for induction of remission in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

Budesonide for maintenance of remission in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

High levels of glucocorticoid receptors in patients with active Crohn's disease may predict steroid resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

Treating Crohn's disease by inducing T lymphocyte apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

An index of inflammatory activity in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

Corticosteroids in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

7 January 2021

Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

7 January 2021

Corticosteroids in the treatment of gastrointestinal disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

7 January 2021

Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

7 January 2021

Immunosuppressant Medications and Mortality in Inflammatory Bowel Disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

7 January 2021

Inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB2

7 January 2021

10.1002/14651858.CD002913.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

19160212

1 reference

Consolidated OpenCitations Corpus – April 2017